Chronic Azithromycin (AZM) is a common treatment for lung infection. Among adults at risk of cardiac events, AZM use has been associated with cardiovascular harm. We assessed cardiovascular safety of AZM among children with CF, as a secondary analysis of a placebo-controlled, clinical trial, in which study drug was taken thrice-weekly for a planned 18 months. Safety assessments using electrocardiogram (ECG) occurred at study enrollment, and then after 3 weeks and 18 months of participation. Among 221 study participants with a median of 18 months follow-up, increased corrected QT interval (QTc) of ≥30 msec was rare, at 3.4 occurrences per 100 person-years; and incidence of QTc prolongation was no higher in the AZM arm than the placebo arm (1.8 versus 5.4 per 100 person-years). No persons experienced QTc intervals above 500 msec. Long-term chronic AZM use was not associated with increased QT prolongation.

中文翻译：

---

长期使用阿奇霉素与囊性纤维化儿童 QT 间期延长无关

慢性阿奇霉素 (AZM) 是肺部感染的常见治疗方法。在有心脏事件风险的成年人中，AZM 的使用与心血管损害有关。我们评估了 AZM 在 CF 儿童中的心血管安全性，作为对安慰剂对照临床试验的二次分析，其中研究药物每周服用三次，计划持续 18 个月。使用心电图 (ECG) 进行的安全性评估发生在研究招募时，然后在 3 周和 18 个月的参与后进行。在中位随访时间为 18 个月的 221 名研究参与者中，校正 QT 间期（QTc）增加≥30 毫秒是罕见的，每 100 人年发生 3.4 次；AZM 组的 QTc 延长发生率不高于安慰剂组（1.8 对 5.4/100 人年）。没有人经历超过 500 毫秒的 QTc 间期。